Literature DB >> 27986978

[Triggers of exanthematous drug eruptions: Stop intake, treat through or desensitization?]

M Absmaier1, T Biedermann1, K Brockow2.   

Abstract

Drug hypersensitivity reactions affect over 7% of the population and are problematic both for patients and doctors. They frequently occur in the form of exanthematous drug eruptions. The clinical manifestation of delayed hypersensitivity reactions is very variable ranging from localized fixed drug eruptions to life-threatening, severe bullous mucocutaneous eruptions or systemic drug hypersensitivity syndromes. In the case of suspicion of an exanthematous drug eruption, the causality should initially be assessed according to the proposed algorithm. If both the chronology and the clinical symptoms are indicative of a delayed drug hypersensitivity reaction, the suspected drug should be avoided. Only in cases of urgent therapeutic indications and if alternative drugs are not available, the options of "treating through" and temporary tolerance induction by "desensitization" should be considered after an individual risk-benefit analysis.

Entities:  

Keywords:  Contraindications; Danger signs; Hypersensitivity; Risk-benefit analysis; Surveillance

Mesh:

Substances:

Year:  2017        PMID: 27986978     DOI: 10.1007/s00105-016-3907-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  21 in total

1.  General considerations for skin test procedures in the diagnosis of drug hypersensitivity.

Authors:  K Brockow; A Romano; M Blanca; J Ring; W Pichler; P Demoly
Journal:  Allergy       Date:  2002-01       Impact factor: 13.146

Review 2.  Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome.

Authors:  Yoko Kano; Tadashi Ishida; Kazuhisa Hirahara; Tetsuo Shiohara
Journal:  Med Clin North Am       Date:  2010-07       Impact factor: 5.456

3.  Drug allergy: an updated practice parameter.

Authors: 
Journal:  Ann Allergy Asthma Immunol       Date:  2010-10       Impact factor: 6.347

Review 4.  Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.

Authors:  Patrice Cacoub; Marc Bourlière; Jann Lübbe; Nicolas Dupin; Peter Buggisch; Geoffrey Dusheiko; Christophe Hézode; Odile Picard; Ramon Pujol; Siegfried Segaert; Bing Thio; Jean-Claude Roujeau
Journal:  J Hepatol       Date:  2011-08-30       Impact factor: 25.083

5.  Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy.

Authors:  Maren Paulmann; Maja Mockenhaupt
Journal:  J Dtsch Dermatol Ges       Date:  2015-07       Impact factor: 5.584

Review 6.  Adverse drug reactions: mechanisms and assessment.

Authors:  Johannes Ring; Knut Brockow
Journal:  Eur Surg Res       Date:  2002 Jan-Apr       Impact factor: 1.745

7.  Rapid desensitization for non-immediate reactions in patients with cystic fibrosis.

Authors:  P Whitaker; N Shaw; J Gooi; C Etherington; S Conway; D Peckham
Journal:  J Cyst Fibros       Date:  2011-03-09       Impact factor: 5.482

Review 8.  Epidemiology of hypersensitivity drug reactions.

Authors:  Eva Rebelo Gomes; Pascal Demoly
Journal:  Curr Opin Allergy Clin Immunol       Date:  2005-08

9.  A 6-month prospective survey of cutaneous drug reactions in a hospital setting.

Authors:  F Fiszenson-Albala; V Auzerie; E Mahe; R Farinotti; C Durand-Stocco; B Crickx; V Descamps
Journal:  Br J Dermatol       Date:  2003-11       Impact factor: 9.302

Review 10.  Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole.

Authors:  D Lin; W K Li; M J Rieder
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.